Prescription medicine
Furosemide Brand names: Lasix, Furoscix
Furosemide (Lasix) is a prescription medicine with an FDA approval on record since 1966. FDA's NDC Directory lists it from 52 generic labelers, and pharmacies paid $0.490 per mL (Furosemide 20 mg/2 mL vial) in the October 7, 2026 NADAC survey.
- Generic listed
- In shortage
Check it at the source: the furosemide FDA label on DailyMed (effective September 30, 2025, Validus Pharmaceuticals LLC); the NDA 16273 record on Drugs@FDA; every furosemide label on DailyMed.
Highlights of the record
FDA label of September 30, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageEdema LASIX is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.
Forms and strengths
- 20 mg
- 40 mg
- 80 mg
- 8 mg/ml
- 10 mg/ml
- 20 mg/2ml
- 30 mg/ml
- 40 mg/4ml
- 40 mg/5ml
- 80 mg/ml
- 100 mg/10ml
Tablet; injection (solution); injection; solution.
On the market
- Earliest approval on file
- July 1, 1966 Lasix, Validus Pharms; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 39 first September 26, 1985; 22 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 63 of which 52 under generic applications, 17 under brand applications, repackagers included
- Last listed patent
- January 10, 2042 Lasix Onyu injection; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.490 per mL Furosemide 20 mg/2 mL vial
- Shortage (FDA)
- 12 of 32 presentations limited or unavailable updated October 6, 2026
- Recalls by its makers (FDA)
- 8 since 2012 1 Class I among all firms' recalls; latest March 20, 2026; 5 more by firms not listed as its makers
- FAERS reports
- 398,354 through July 30, 2026
What is furosemide used for?
From the label: indications and usageEdema LASIX is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. LASIX is particularly useful when an agent with greater diuretic potential is desired. Hypertension Oral LASIX may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with LASIX alone.
Conditions named in the indications of furosemide's FDA labels, with every medicine labeled for each:
From other furosemide labelsHeart failure: INDICATIONS AND USAGE Edema LASIX is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.
Edema (fluid retention): Furosemide is indicated as adjunctive therapy in acute pulmonary edema.
FDA pharmacologic class: Loop Diuretic.
Source: FDA drug label (Lasix), Validus Pharmaceuticals LLC, effective September 30, 2025 (SPL set 2c9b4d8f-0770-482d-a9e6-9c616a440b1a), via openFDA; the full label on DailyMed
Is there a generic for furosemide (Lasix)?
The FDA approved the first generic furosemide on September 26, 1985. 39 generic applications are approved; 22 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists furosemide from 52 labelers under a generic (ANDA) application and from 17 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 3 patents for Lasix Onyu injection, the last expiring on January 10, 2042. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 1966 earliest approval on file
- 1985 first generic approved
- 2042 last listed patent
- 2020 to now in shortage
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for furosemide (Lasix)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.490 per mL (Furosemide 20 mg/2 mL vial), up 31% from $0.375 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Furosemide 20 mg/2 mL vial (generic)
- Lasix 20 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Furosemide 1,000 mg/100 mL vial | Generic | $0.253 per mL | n/a | +13% |
| Furosemide 10 mg/mL solution | Generic | $0.092 per mL | n/a | -3% |
| Furosemide 100 mg/10 mL vial | Generic | $0.253 per mL | $2.53 per vial | +13% |
| Furosemide 20 mg tablet | Generic | $0.026 per tablet | $0.781 | -3% |
| Furosemide 20 mg/2 mL vial | Generic | $0.490 per mL | $0.980 per vial | +31% |
| Furosemide 40 mg tablet | Generic | $0.0291 per tablet | $0.873 | -9% |
| Furosemide 40 mg/4 mL oral solution cup | Generic | $0.092 per mL | n/a | n/a |
| Furosemide 40 mg/4 mL vial | Generic | $0.253 per mL | $1.01 per vial | +13% |
| Furosemide 500 mg/50 mL vial | Generic | $0.490 per mL | $24.51 per vial | +31% |
| Furosemide 80 mg tablet | Generic | $0.0498 per tablet | $1.49 | -9% |
| Lasix 20 mg tablet | Brand | $0.749 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $22.46 | +0.1% |
| Lasix 40 mg tablet | Brand | $1.05 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $31.48 | -0.2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is furosemide in shortage?
The FDA Drug Shortage Database lists 12 of 32 furosemide presentations as limited or unavailable (updated October 6, 2026); the first entry was posted on April 7, 2020. 17 more presentations are on the list as available.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08) | Accord Healthcare Inc. | Current | October 3, 2026 |
| Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43) | Accord Healthcare Inc. | Current | October 3, 2026 |
| Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43) | Accord Healthcare Inc. | Current | October 3, 2026 |
| Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41) | Avet Pharmaceuticals, Inc. | Current | October 5, 2026 |
| Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42) | Avet Pharmaceuticals, Inc. | Current | October 5, 2026 |
| Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44) | Avet Pharmaceuticals, Inc. | Current | October 5, 2026 |
| Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02) | Gland Pharma Limited | Current | July 22, 2026 |
| Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04) | Gland Pharma Limited | Current | July 22, 2026 |
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has furosemide been recalled?
The FDA's Enforcement Report lists 13 recalls naming furosemide since 2012: 1 Class I (the most serious), 10 Class II, 2 Class III; 3 still ongoing. 5 of them are by firms that FDA's NDC Directory does not list as a maker of furosemide and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 20, 2026 | Class II | Leading Pharma, LLC | CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit. |
| January 10, 2026 | Class II | Graviti Pharmaceuticals Private Limited | Presence of Foreign Substance |
| August 27, 2018 | Class I | SCA Pharmaceuticals, Inc. not a listed maker | Presence of Precipitate: Customer complaint for visible precipitate in product believed to be the active ingredient furosemide. |
| December 22, 2016 | Class II | Roxane Laboratories, Inc. | Failed Tablet/Capsule Specifications: An unusually thick tablet was reported through a complaint. |
| October 19, 2015 | Class II | Western Drug | Lack of Assurance of Sterility |
| September 25, 2015 | Class III | Boehringer Ingelheim Roxane Inc | CGMP Deviations: The active pharmaceutical ingredient (API) intended for use in furosemide oral solution USP was inadvertently used to manufacture the recalled … |
| July 26, 2013 | Class II | Beacon Hill Medical Pharmacy, P.C. not a listed maker | Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance |
| May 29, 2013 | Class II | Lowlite Investments, Inc. D/B/A Olympia Pharmacy not a listed maker | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the furosemide label say about other medicines?
The furosemide label names 9 other medicines in its interaction, contraindication or warning sections. The labels of 45 other medicines name furosemide. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Cisplatin | drug interactions | There is a risk of ototoxic effects if cisplatin and LASIX are given concomitantly. |
| Cyclosporine | drug interactions | Concomitant use of cyclosporine and LASIX is associated with increased risk of gouty arthritis secondary to LASIX-induced hyperurecemia and cyclosporine impairment of renal urate excretion. |
| Ethacrynic acid | drug interactions | LASIX should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity. |
| Indomethacin | drug interactions | Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of LASIX (furosemide) in some patients by inhibiting prostaglandin synthesis. |
| Lithium | drug interactions | Lithium generally should not be given with diuretics because they reduce lithium’s renal clearance and add a high risk of lithium toxicity. |
| Methotrexate | drug interactions | Methotrexate and other drugs that, like LASIX, undergo significant renal tubular secretion may reduce the effect of LASIX. |
| Phenytoin | drug interactions | There is evidence that treatment with phenytoin leads to decreased intestinal absorption of LASIX, and consequently to lower peak serum furosemide concentrations. |
| Succinylcholine | drug interactions | LASIX has a tendency to antagonize the skeletal muscle-relaxing effect of tubocurarine and may potentiate the action of succinylcholine. |
| Sucralfate | drug interactions | Simultaneous administration of sucralfate and LASIX tablets may reduce the natriuretic and antihypertensive effects of LASIX. |
Other labels that name furosemide
- Aliskiren
- Amikacin
- Arsenic trioxide
- Atenolol
- Bumetanide
- Cabozantinib
- Captopril
- Cefepime
- Cefotaxime
- Ceftazidime
- Celecoxib
- Colestipol
- Diclofenac
- Diflunisal
- Epoprostenol
- Etodolac
- Fenoprofen
- Ferric oxyhydroxide
- Fludrocortisone
- Ibuprofen
- Ketoprofen
- Ketorolac
- Leflunomide
- Meclofenamate
- Mefenamic acid
- Meloxicam
- Metolazone
- Nabumetone
- Naproxen
- Neomycin
- Oxaprozin
- Piroxicam
- Ramipril
- Sodium zirconium cyclosilicate
- Streptomycin
- Sulindac
- Tamsulosin
- Teriflunomide
- Tobramycin
Source: FDA drug label (Lasix), Validus Pharmaceuticals LLC, effective September 30, 2025 (SPL set 2c9b4d8f-0770-482d-a9e6-9c616a440b1a), via openFDA; the full label on DailyMed
What do FAERS reports show for furosemide?
The FDA Adverse Event Reporting System holds 398,354 reports that list furosemide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 61,850 are coded as a death and 195,229 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as furosemide?
30 other medicines are given the same way (oral) and in the same FDA class as furosemide or labeled mainly for the same use (heart failure), the same class first. Heart failure lists all 37 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Bumetanide | Heart failure | 24 labelers | $0.108 per tablet 1 mg tablet | Resolved |
| Torsemide | High blood pressure, Heart failure | 20 labelers | $0.0636 per tablet 20 mg tablet | No current entry |
| Ethacrynic acid | Heart failure | 8 labelers | $0.807 per tablet 25 mg tablet | No current entry |
| Metoprolol | High blood pressure, Heart failure | 64 labelers | $0.085 per tablet 100 mg tablet | A presentation being discontinued |
| Lisinopril | High blood pressure, Heart failure | 36 labelers | $0.0254 per tablet 20 mg tablet | No current entry |
| Carvedilol | High blood pressure, Heart failure | 41 labelers | $0.0179 per tablet 6.25 mg tablet | No current entry |
| Spironolactone | High blood pressure, Heart failure | 38 labelers | $0.0426 per tablet 25 mg tablet | A presentation being discontinued |
| Hydrochlorothiazide | High blood pressure, Heart failure | 44 labelers | $0.0115 per tablet 25 mg tablet | A presentation being discontinued |
Every medicine labeled for the same conditions as furosemide
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does furosemide compare with medicines for the same use?
13 side-by-side pages set furosemide beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to furosemide
- 30 medicines for the same use
- Other loop diuretics
- the pharmacologic class, with prices and generics
- Furosemide side effects
- the label's list beside FAERS reports
- Furosemide shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other